OSCAR GALINDO: Open Payments
NPI 1639325178 · CUDAHY, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,625 in 99 payments from 22 companies in 2025. Trend: 2023 $2,155 · 2024 $2,004 · 2025 $3,625
Food & beverage: $3,625
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $663 |
| Amgen Inc. | 22 | $557 |
| AstraZeneca Pharmaceuticals LP | 9 | $357 |
| CeQur Corporation | 1 | $283 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $210 |
| Merck Sharp & Dohme LLC | 7 | $197 |
| Kowa Pharmaceuticals America, Inc. | 2 | $132 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $125 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $125 |
| Travere Therapeutics, Inc. | 1 | $125 |
Products named: REPATHA, CeQur Simplicity, Wegovy, OTEZLA, Kerendia, Ozempic, VERQUVO, BREZTRI.
Industry payments across CA — which companies pay providers there.
